Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Bifidobacterium Longum for Skin Barrier Dysfunction in Obesity
NCT07184905Completed
- Sponsor
- Shenzhen People's Hospital
- Start
- Sep 2025
- Primary completion
- Oct 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, double-blind trial of bifidobacterium longum in skin barrier dysfunction (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: Transepidermal Water Loss at 1 month. Started Sep 2025; status: completed.
02
Drugs
bifidobacterium longum
03
Conditions
skin barrier dysfunction
Beyond the preview
Go deeper on NCT07184905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184905.